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Abstract
Genome-wide expression analysis using next generation sequencing (RNA-Seq) provides an opportunity for in-depth
molecular profiling of fundamental biological processes, such as cellular differentiation and malignant transformation.
Differentiating human neurons derived from induced pluripotent stem cells (iPSCs) provide an ideal system for RNA-Seq
since defective neurogenesis caused by abnormalities in transcription factors, DNA methylation, and chromatin modifiers lie
at the heart of some neuropsychiatric disorders. As a preliminary step towards applying next generation sequencing using
neurons derived from patient-specific iPSCs, we have carried out an RNA-Seq analysis on control human neurons. Dramatic
changes in the expression of coding genes, long non-coding RNAs (lncRNAs), pseudogenes, and splice isoforms were seen
during the transition from pluripotent stem cells to early differentiating neurons. A number of genes that undergo radical
changes in expression during this transition include candidates for schizophrenia (SZ), bipolar disorder (BD) and autism
spectrum disorders (ASD) that function as transcription factors and chromatin modifiers, such as POU3F2 and ZNF804A, and
genes coding for cell adhesion proteins implicated in these conditions including NRXN1 and NLGN1. In addition, a number
of novel lncRNAs were found to undergo dramatic changes in expression, one of which is HOTAIRM1, a regulator of several
HOXA genes during myelopoiesis. The increase we observed in differentiating neurons suggests a role in neurogenesis as
well. Finally, several lncRNAs that map near SNPs associated with SZ in genome wide association studies also increase
during neuronal differentiation, suggesting that these novel transcripts may be abnormally regulated in a subgroup of
patients.
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Introduction
Research on the biological basis of SZ and other neuropsy-
chiatric disorders has been hampered by the inaccessibility of the
human brain. However, the discovery of iPSC technology has
the potential to address this problem by providing investigators
with patient-specific neurons that can be used for disease
m o d e l i n g .I nt h ep a s tf e wy e a r s ,i n v e s t i g a t o r sh a v et a k e na d -
vantage of this opportunity to establish iPSC lines in a variety
of neuropsychiatric disorders including Rett Syndrome, Parkin-
son Disease, Amyotrophic Lateral Sclerosis, Familial Dysauto-
nomia, and most recently, SZ [1–12]. In the study reported by
Brennand et al. neurons derived from SZ-specific iPSCs showed
diminished neuronal connectivity, reduced PSD95-protein levels
and altered expression of WNT signaling pathways [1]. Simi-
larly, we have also been developing iPSC lines from patients with
SZ, a data set that includes patients with 22q11.2 deletions (in
press).
In addition to their utility for disease modeling in neuropsychi-
atric problems, iPSCs can also be used to study early differenti-
ating human neurons in vitro to gain insight into neurogenesis,
which is particularly relevant to both SZ and ASD considering
that both appear to have a neurodevelopmental basis [13–16].
With these aspects of disease pathogenesis in mind, we have
analyzed the transcriptome of human neurons derived from iPSCs
using RNA-Seq, a method that provides increased sensitivity
with the capacity to detect low-copy transcripts, novel transcripts,
lncRNAs, and splice isoforms [17–20]. The key role played by cell
type-specific splicing in neuronal differentiation, particularly in
genes coding for cell adhesion proteins, and the growingrecognition
that lncRNAs play a role neurogenesis lend further support for the
value of deep sequencing transcriptome analysis [21–23].
Finally, a global, unbiased transcriptome analysis could help
determine the biological significance of SNP markers associated
with neuropsychiatric disorders identified in GWAS carried out in
SZ, ASD, BD, many of which map to intergenic regions or deep
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found [24–26].
Our findings show that early differentiating neurons undergo an
extraordinary array of quantitative changes in gene expression and
in splice isoform generation, similar to that reported in diffe-
rentiating human neurons derived from human embryonic stem
cells (hESCs) [27]. In addition, we describe dramatic changes in
expression of lncRNA genes during differentiation, one of which is
HOTAIRM1, a cis-acting regulator of the HOXA cluster during
myelopoiesis [28]. Contrary to previous reports suggesting that
HOTAIRM1 is not expressed in brain, a 54.6-fold increase in
transcripts was detected in differentiating neurons, suggesting a
novel role in neural differentiation. In addition, some GWAS
SNPs found in SZ, BD and ASD mapped to lncRNA genes that
are expressed in differentiating neurons, suggesting a role for these
novel regulators in a subgroup of patients.
Methods
This study was approved by the Internal Review Board of the
Albert Einstein College of Medicine (protocol number 1996-013).
Informed consent was obtained and the data were analyzed
anonymously in accordance with the Declaration of Helsinki.
iPSCs and neural differentiation
Details regarding the generation of iPSCs and the neuronal
differentiation protocol used are described in Text S1.
RNA-Seq
Total RNA was isolated from cells using the miRNeasy Kit
(Qiagen) according to the manufacturer’s protocol. An additional
DNase1 digestion step was performed to ensure that the samples
were not contaminated with genomic DNA. RNA purity was
assessed using the ND-1000 Nanodrop. Each RNA sample had an
A260:A280 ratio above 1.8 and A260:A230 ratio above 2.2.
Briefly, total RNA (25 ng) was converted to cDNA using the
NuGEN Ovation RNA-Seq System according to the manufactur-
er’s protocol (NuGEN, San Carlos, CA, USA). The protocol
employs a single primer isothermal amplification (SPIA) method to
amplify RNA target into double stranded cDNA under standard-
ized conditions that markedly deplete rRNA without preselecting
mRNA. cDNA was then used for Illumina sequencing library
preparation using Encore NGS Library System I. NuGEN-
amplified double-stranded cDNA was fragmented into ,300 base
pair (bp) using a Covaris-S2 system. DNA fragments (200 ng) were
then end-repaired to generate blunt ends with 59 phosphatase and
39 hydroxyls and adapters were ligated for paired end sequencing
on Illumina HiSeq 2000. The purified cDNA library products
were evaluated using the Agilent bioanalyzer and diluted to
10 nM for cluster generation in situ on the HiSeq paired-end flow
cell using the CBot automated cluster generation system followed
by massively-parallel sequencing (26100 bp) on HiSeq 2000. We
obtained 104-bp mate-paired reads from DNA fragments of
average length of 250-bp (standard deviation for the distribution of
inner distances between mate pairs is approximately 50 bp). iPSC
and neuron RNA-Seq reads were separately aligned to the human
genome (GRCh37/hg19) using the software TopHat (version
1.1.4) [29].
Splice junctions were automatically determined by TopHat,
with the provided guidance of annotated gene models (GTF file)
obtained mainly from Ensembl (http://www.ensembl.org). In our
analysis, all three splice sites, ‘‘GT-AG’’, ‘‘GC-AG’’ and ‘‘AT-AC’’
were considered. All splicing junctions supported by at least one
high-quality mapped read were kept. The option for searching
novel splice variants in Tophat was left on. The resulting
alignment data from Tophat were then fed to an assembler
Cufflinks (version 0.9.3) to assemble aligned RNA-Seq reads into
transcripts [29]. Annotated transcripts were obtained from the
UCSC genome browser (http://genome.ucsc.edu) and the
Ensembl database; the category of transcripts was described at
http://vega.sanger.ac.uk/info/about/gene_and_transcript_types.
html. The number of transcripts in each category is listed in
Table 1. Transcript abundances were measured in Fragments Per
Kilobase of exon per Million fragments mapped (FPKM), which
originated from the idea of RPKM (Reads per Kilobase per
Million) [19]. To address the common issue in the assembly that a
Table 1. RNA-Seq Summary.
Down-regulated from day 0 to 10 Up-regulated from day 0 to 10 Total number of genes
Total 5953 3055 50047
lincRNA 220 228 1443
miRNA 12 6 1809
Misc. RNA 18 30 1190
Proc. transcript 535 639 9062
Protein coding 4060 1808 21598
pseudogene 1052 319 10923
snoRNA 11 5 1523
snRNA 6 3 1951
rRNA N/A 1 535
rRNA p. gene 22 2 179
scRNA p. gene 17 14 787
Abbreviations: lincRNA (long intergenic non-coding RNA); miRNA (microRNA); proc. (processed) (processed transcripts also known as lncRNA – long non-coding RNA);
Misc. RNA (miscellaneous RNA, also includes mitochondrial RNA, mitochondrial transfer RNA, mitochondrial ribosomal RNA, polymorphic pseudogene); p. gene
(pseudogene); snoRNA (small nucleolar RNA); snRNA (small nuclear RNA); rRNA (ribosomal RNA); scRNA (small cytoplasmic RNA).
Number (N) of RNA-Seq reads: Day 0: N of reads [pairs] 269,672,486 [134,836,243]; N of paired-match reads 121,620,928 [60,810,464]; N of single-match reads 39,276,866:
Day 10: N of reads [pairs], 222,127,542 [111,063,771]; N of paired-match reads 115,280,074 [57,640,037], N of single-match reads 33,721,936.
doi:10.1371/journal.pone.0023356.t001
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transcripts within the same genetic locus, maximum likelihood
estimation was performed by Cufflinks based on a numerical
optimization algorithm for calculating FPKM. Finally, the
program Cuffdiff was used to define differential expression [29].
Instead of using transcript abundances computed separately by
Cufflinks for each condition, Cuffdiff took alignment data from
both iPSC and day 10 neurons, together with a list of human
genome annotations (the same GTF file as used above, including
both coding and non-coding transcripts) to infer expression
differences at the level of transcript isoforms or primary transcripts
or genes. Since we only had one replicate, the variance of FPKM
was directly estimated from read counts using Poisson distribution,
as described in detail at the Cufflinks website (http://cufflinks.
cbcb.umd.edu/howitworks.html#hdif). In brief, the counts of
reads that mapped to all nucleotides within a gene/transcript were
assumed to follow Poisson distribution and then their mean was
used as the variance. Student’s t-test was then used to find
significantly differentially expressed transcripts, with the test
statistic derived from the log ratio of FPKM values in our two
samples (see Cufflinks website for further details). To overcome the
known bias in data normalization arising from a small number of
highly expressed genes, we normalized our iPSC and neuronal
data with total number of fragments mapped to the upper quartile
of high expressed genes/transcripts rather than total mapped
fragments [30].
Validation by reverse transcriptase PCR (RT-PCR) and
quantitative real time PCR (qPCR)
Selected genes and splice variants were validated by RT-PCR
and qPCR using standard protocols that are described in detail in
the Text S1. The primers used in these analyses are shown
Table S1.
Results
Complementary DNA was generated using RNA extracted
from iPSCs and a 10 day cluster of neurons. Samples were
amplified prior to paired-end deep sequencing as described in the
methods section. More than 1610
8 pairs of reads were obtained
for each sample, of which 74.3% and 82.3% had at least one end
mapped to the reference genome (see legend Table 1 for details).
The expression of 9008 genes was significantly altered as the iPSCs
differentiated into neurons (q-value,0.05) (Table 1) (for a
complete list of genes that showed significant changes in
expression see Table S2). Of these, 5953 genes decreased in
expression, while 3055 genes increased. Although the majority of
these significantly altered genes were protein coding (4060 and
1808, respectively), approximately one-third were non-coding,
findings similar to previous reports showing widespread expression
in both coding and non-coding regions [31–34].
Consistent with the differentiation of iPSCs into neurons,
substantial 10 to .1,000-fold decreases were detected in the
expression of genes associated with pluripotency such as OCT4
(POU5F1), JARID2, NANOG, and LIN28A, with a concomitant
increase in expression of transcription factors associated with
neural differentiation, including POU3F2, MYT1L, NEUROD1,
and MEF2C (Table S3). MYT1L, POU3F2, along with ASCL1, are
transcription factors capable of converting fibroblasts directly into
neurons [35].
The most highly expressed genes in iPSCs were TPT1, PTMA,
NCL, NASP, and HSP90AB1. TPT1 (tumor protein, translationally-
controlled 1) is involved in maintaining embryonic stem cell
phenotype and interacts with OCT4 and NCL (nucleolin), a
nucleolar phosphoprotein involved in ribosomal maturation [36–
38]. PTMA (prothymosin, alpha isoform 2) is over-expressed in a
number of different cancers and interacts with histone acetyl-
transferases. NASP codes for nuclear autoantigenic sperm protein
isoform 2 a histone H1 binding protein expressed in all dividing
cells, inhibits proliferation and induces apoptosis in prostate cancer
PC-3 cells, and is one of the hub genes involved in maintaining
stem cell fate [39].
Among the most highly expressed genes in neurons were TPT1,
TUBA1B, HNRNPA2B1, C5orf13, RPS6, NCL, CANX, and RPL35A.
C5orf13 is neuronal protein 3.1 isoform A and is expressed in fetal
and adult brains. Ribosomal protein S6 (RPS6) is phosphorylated
in response to an array of growth factors and mitogens, a process
that may be disrupted in Rett Syndrome [40]. However, among
the top 25 genes that are the most highly expressed in neurons, all
show higher levels of expression in iPSCs.
More interesting are the genes that show the most dramatic
shifts in gene expression – both increases and decreases – during
the transition from iPSCs to neurons. Among the transcripts that
decreased radically were SCGB3A2, POU5F1, DMKN, C14orf115,
PRDM14, HLA-DPB2, POU5F1P1, TRIML2, MT1F, MT1X,
CYP2S1, and IDO1. SCGB3A2 (secretoglobin, family 3A, member
2 precursor) maps to 5q32 and is a downstream target of the
homeodomain transcription factor NKX2-1, which is critical for
the development of lung, thyroid and ventral forebrain [41].
DMKN (dermokine isoform 1 precursor) is primarily expressed in
skin and its expression in iPSCs is probably due to residual
expression of fibroblast specific genes. PRDM14 is a member of the
PR domain and zinc finger proteins involved in transcriptional
regulation. It is expressed in pluripotent stem cells and is involved
in mouse embryonic stem cell (mESC) self-renewal, overlapping
with Nanog and Oct4 in its binding domain [42]. In addition,
PRDM14 regulates the expression of OCT4 and is part of the
network of genes involved in reprogramming human fibroblasts
[43]. Finally, POU5F1P1 may be a processed pseudogene or codes
for a protein that binds to the nucleus that is believed to be
involved in malignant transformation [44–46].
Considering the high level of expression in iPSCs and the
rapid and dramatic decline that occurs during differentiation,
some of these genes could be candidates for maintaining
pluripotency or modulating cell type or region specific neural
differentiation.
Another gene that showed one of the most significant fold-
decreases during neuronal differentiation is FZD5 (frizzled 5
precursor), a receptor for WNT5A, which is particularly in-
teresting in the context of neuropsychiatric disorders because
signaling through canonical WNT-mediated signal transduction
appears to be involved in SZ and BD in subgroups of patients
[1,47–50]. Down regulation of FZD5 mediated signal transduc-
tion, similar to that described in differentiating hESCs, is
consistent with a role in maintaining pluripotency [27].
L1TD1 codes for LINE-1 type transposase domain containing 1.
This gene appears to be a partner in the Oct4 interactome based
on a protein affinity-based assay [51]. There is some evidence that
L1 retrotransposition occurring selectively in neuronal progenitor
cells could be a factor in brain development [52,53].
Among the genes that showed the largest fold increase in
expression during the transition from iPSCs to neurons was
CARTPT (also known as CART), which codes for a neuropeptide
involved in regulating food intake, reward and endocrine functions
[54]. It is expressed in the hypothalamus and throughout the
mesocorticolimbic dopamine reward system (nucleus accumbens
shell, amygdala complex, extended amygdala and orbitofrontal
cortex [55,56].
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stathmin family that encode phosphoproteins involved in regulat-
ing the microtubule filament system in the brain, the AMPA2
receptor gene GRIA2, ZIC4, a zinc finger transcription factor
expressed in the dorsal midline of the forebrain and in the
boundary between the diencephalon and telencephalon, SCN3A,
which codes for a sodium channel, voltage-gated, type III, alpha
subunit and has been implicated in seizure disorders and
neuropsychiatric problems, EPHA3, an ephrin receptor, the
potassium channel encoding KCNK2, DCC (deleted in colorectal
cancer) which codes for a receptor for the axon guidance protein
netrin-1, and SYT4 (synaptotagmin 4), a negative regulator of
oxytocin release [57–59].
Several members from each of the four HOX families are among
the most differentially expressed genes. HOX genes are involved in
brain patterning in the development of forebrain, midbrain and
hindbrain, and abnormal expression has been implicated in
mental retardation, subtypes of ASD, and epilepsy [60–62].
Finally, previous work from our lab shows that the differenti-
ation method we use results primarily in the development of
glutamatergic neurons. This is reflected in the gene expression
profile here, which shows that the glutamate transporter,
SLC17A6,( VGLUT2) is among the most highly differentially
expressed genes (Tables S2 and S3). By contrast, SLC32A1
(VGAT, GABA vesicular transporter), SLC6A20 (NET, norepi-
nephrine transporter), SLC6A4 (SERT, serotonin transporter), and
SLC18A1 and SLC18A2 (VMAT1 and VMAT2A; vesicular
monoamine transporters) were not expressed. The dopamine
transporter gene, SLC6A3, (DAT1) was expressed, but at 1/50
th
the level of SLC17A6 (Table S2).
The list of significantly altered genes was subjected to
bioinformatics analysis using Gene Ontology (GO) to determine
functional enrichment [63]. This showed changes in gene
expression that were consistent with the conversion of pluripotent
stem cells into terminally differentiated neurons (Table 2). In
addition, there was high correlation (R=0.64) between the results
obtained with pre-amplified RNA using RNA-Seq and total RNA
using standard microarray expression profiling (Fig. 1). The
findings show that faithful amplification of RNA can be achieved,
which is important for studying gene expression profiles in small
numbers of neurons.
lcnRNAs and lincRNAs
A substantial fraction of transcripts in mammalian genomes do
not code for proteins. These include lncRNAs and lincRNAs (long
intergenic non-coding RNAs), which are arbitrarily defined as
greater than 200 bases in length, to distinguish them from
functional small non-coding transcripts, such as microRNAs
(miRNAs), piwi-interacting RNAs (piRNAs), and small nucleolar
RNAs (snoRNAs).
LncRNAs (also known as processed transcripts) by definition are
found within protein coding genes, overlapping with promo-
ters, exons or introns in either sense or antisense orientations.
LincRNAs, on the other hand, are found in intergenic regions.
Two well-known lncRNAs are Xist, which initiates X-chromo-
some inactivation in females and HOTAIR, which is embedded
within the HOXC locus, but has a trans-repressive effect on HOXD
expression [64–66]. Other lncRNAs involved in regulating HOX
gene expression are HOTAIRM1 and HOTTIP [28,67]. There is
increasing evidence that lncRNAs are involved in stem cell
pluripotency and brain development [22,68–70]. Khalil et al
showed that ,20% of lincRNA bind to polycomb repressive
complex 2 (PRC2), suggesting that many regulate gene expression
at the chromatin level [71].
As shown in Table 1, 1622 non-coding genes (including lncRNAs
and lincRNAs) significantly increased or decreased in expression
during the transition from iPSCs to neurons. The most abundantly
expressed lincRNAs in iPSCs are MALAT1, SNHG6, SNORD87,
CRNDE,a n dPVT1 (Table S4). MALAT1 (metastasis-associated lung
adenocarcinoma transcript 1) is also the most abundantly expressed
lincRNA in differentiating neurons. It was initially identified in a screen
for genes differentially expressed in metastatic non-small cell carcinoma
[72]. MALAT1 appears to play a role in alternative splicing of pre-
mRNAs since it localizes to nuclear speckles, dynamic structures that
are essentially concentrations of splicing factors; it also recruits SR
proteins, which participate in maturation of the splicosome [73–75].
MALAT1 is up-regulated in the brains of PCP-treated mice and plays a
role in hippocampal synaptic function [76]. Although the difference in
expression between iPSCs and day 10 neurons was statistically
Table 2. Gene Ontology (GO) terms for differentially
expressed genes.
GO TERMS FOR DOWN-REGULATED GENES
p-value Benjamani
RNA processing 6.7E-56 3.1E-52
Translation 1.4E-44 3.2E-41
mRNA metabolic process 9.7E-36 1.5E-32
cell cycle 6.0E-35 6.9E-32
RNA Splicing 1.7E-33 1.6E-30
mRNA processing 7.2E-33 5.5E-30
RNP complex biogenesis 3.0E-31 2.0E-28
ribosomal biogenesis 3.8E-30 2.2E-27
mitotic cell cycle 4.6E-29 2.4E-26
cell cycle phase 2.6E-27 1.2E-24
DNA metabolic process 5.3E-27 2.2E-24
Cell cycle phase 1.2E-23 4.6E-21
translational elongation 1.7E-23 6.0E-21
RNA splicing via transester. 3.1E-23 1.0E-20
Nuclear mRNA splicing 3.1E-23 1.0E-20
rRNA metabolic process 7.3E-23 2.2E-20
ncRNA metabolic process 9.7E-23 2.8E-20
GO TERMS FOR UP-REGULATED GENES
Neuron Differentiation 41.E-20 1.3E-16
Cell progection morph. 4.7E-18 8.2E-15
Pattern specification 1.3E-17 1.5E-14
Cell morphogenesis 2.1E-17 1.8E-14
Cell morph. Involved in diff. 5.8E-17 7.8E-14
Cell part morphogenesis 6.0E-17 6.5E-14
Cell adhesion 3.3E-16 1.7E-13
Biological adhesion 4.7E-16 1.9E-13
Regionalization 1.0E-15 3.9E-13
Cell morph. in neuron diff. 1.2E-15 4.3E-13
Axonogenesis 1.5E-15 4.9E-13
Ant/post pattern form. 2.2E-15 6.2E-13
Neuron projection morph. 3.1E-15 8.4E-13
Cellular component morph. 1.1E-14 2.7E-12
Neuron development 1.5E-14 3.5E-12
doi:10.1371/journal.pone.0023356.t002
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surprise, there was a substantial difference in splice isoforms generated
in iPSCs and neurons, including several that were specific to each (Fig.
S1). The importance of this finding will require further study.
SNHG6/SNORD87 code for nucleolar RNAs, and PVT1 is
non-coding RNA oncogene that regulates and is regulated by c-myc
[77]. AL445670.1 is highly expressed in iPSCs and decreases 41-
fold in neurons.
Among the lincRNAs that show the largest fold increases in
neurons is CRNDE, a non-coding RNA of unknown function.
CRNDE maps to 16q12.2, near the IRX5 gene, a member of the
Iroquois homeobox family, which are involved in brain patterning
and neurogenesis [78,79]. The close proximity to IRX5 suggests
that CRNDE may influence its expression.
Among the most highly expressed lncRNAs expressed in iPSCs
are XIST, AC00967.5/METTL5, SNHG5/SNORD50, STMN1,
and RP11-509I21.1,RP11-509I21.2,TDGF1 (Table S5). Embryon-
ic stem cells from female mice are characterized by the absence of
XIST expression resulting in activation of both X-chromosomes,
one of which is subsequently randomly inactivated upon differen-
tiation. However in human ESCs and iPSCs, XIST expression is
heterogeneous, resulting in various patterns of X-chromosome
inactivation;linesthatdo not expressXIST show expressionofgenes
from both X-chromosomes [64,80]. The iPSC line used in this
RNA-Seq analysis was from a female.
AC00967.5 maps to 2q31.1 and overlaps with the METTL5
(methyltransferase like 5) gene. It decreases 6-fold in neurons.
RP11-509I21.1 and RP11-509I21.2 overlap with the OCT4 target
TDGF1 (teratocarcinoma-derived growth factor 1; also known as
CRIPTO) and is closely juxtaposed to the tumor suppressor gene
LRRC2 (leucine rich repeat containing 2) [81,82]. A .1,000-fold
decrease in expression of transcripts in this region was found
during the transition from iPSCs to neurons. TDGF1 is protein
coding and is involved in NODAL signaling, which is a
developmental program affecting midline, forebrain and left-right
axis development [83]. Other lncRNAs that are highly expressed
in iPSCs but decrease more than 50-fold in day 10 neurons include
RP11-132A1.3, RP3-430A16.1, RP3-430A16.1, RP11-1144P22.1,
RP11-509I21.1/RP11-509I21.2/TDGF1, RP11-498P14.2, RP11-
366M4.3, AC005062.2/AC007001.3/MACC1. Some of these
genes should be viewed as potential candidates for maintaining
pluripotency.
Amongthe most interestinglncRNAsthatshowmarkedincreases
in expression in neurons is HOTAIRM1, which was suggested to be
specific for myeloid cells [28]. However, we detected a 54.6-fold
increase in transcripts in early differentiating neurons. Also, several
other lncRNAs that map to HOX clusters showed dramatic
increases in expression in day 10 neurons, including RP11-
357H14.12 and AC036222.1, which map to the HOXB locus.
Other lncRNAs that show little or no expression in iPSCs, but
significantly increase in early differentiating neurons, include CTA-
211A9.5/MIAT, RP11-732M18.3, AC018730.1, AC011306.2,
RP11-65D13.1, and CTB-12O2.1. AC018730.1 is only ,2kb
upstream from POU3F3 (BRN-1), a member of the brain-expressed
POU family of transcription factors that is transcribed in the
opposite orientation. Whether or not they share a common
promoter, as we previously described for closely aligned genes
transcribed in opposite orientations, remains to be seen [84].
POU3F3 was not expressed in either the iPSC or neuron sample
used in the RNA-Seq experiment.
Validation by RT-PCR and q-PCR
The expression of some of these non-coding elements was
validated using RT-PCR and qPCR (Fig. 2). Considering the
importance of HOX genes in neuronal migration and brain
patterning, we focused primarily on those that map to the HOX
loci since lncRNAs are known to be involved in their regulation.
The RNA samples used in the validation were not amplified and
were obtained from an independent set of neurons. AC018730.1
transcripts, for example, could not be detected in iPSCs, but were
abundant in both day 14 and 27 neurons. In addition, it is
expressed in both fetal and adult brain samples. Similarly,
HOTAIRM1 RNA was detected in differentiating neurons but
not iPSCs. However, in contrast to AC018730.1, expression in
brain was restricted to the 9 week fetal sample. Expression of the
other lncRNAs in the HOX gene loci - AC036222.1 and RP11-
357H14.12 - was restricted to early differentiating neurons, and
could not be detected in either fetal or adult brain. These findings
suggest that the lncRNAs within the HOXA and HOXB loci are
involved in early neurogenesis and brain development, and
regulate expression of the HOX genes, and perhaps others, within
specific developmental time frames.
We also validated the expression of CRNDE and MIAT by RT-
PCR; lncRNAs that were highly expressed in both iPSCs and
neurons. As seen in Fig. 2, there is a visible band in iPSCs that
appears to increase in early differentiating neurons, similar to the
RNA-Seq findings, which showed detectable transcripts in iPSCs
that increased 3.7 and 3.6-fold in neurons (CRNDE and MIAT,
respectively). Interestingly, CRNDE is expressed in fetal brain but
transcripts could not be detected in adult brain samples, whereas
MIAT is expressed in both.
qPCR was used to quantify the difference in expression in the
un-amplified RNA samples. As seen in Fig. 2, a significant increase
in expression was detected for both using qPCR that was in a
range similar to that observed in the amplified RNA-Seq sample
(CRNDE: 4.3-fold+/22.1; MIAT: 8.7-fold+/25.1; n=3 or 4, each
qPCR determination carried out in triplicate, p=0.05 for both).
In addition to long non-coding RNAs, small non-coding RNAs
were also found to be differentially expressed (Table 1). However,
considering that the RNA amplification method we used does not
accurately amplify small RNAs, the findings will not be discussed
Figure 1. Comparison of fold-changes (log2-transformed) of
gene expression between iPSCs and day 10 neurons as
measured by RNA-Seq (x-axis) and Affymetrix microarray (y-
axis).
doi:10.1371/journal.pone.0023356.g001
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prepared from an unamplified sample is currently being carried
out).
Pseudogenes
Some pseudogenes appear to be biologically functional with
proposed effects on regulating gene expression through a variety of
means, including acting as a miRNA decoy and producing
endogenous short interfering RNAs [46,84–89]. The expression of
1371 pseudogenes changed significantly during the transition from
iPSCs to neurons (Table 1).
The most highly expressed in both iPSCs and day 10 neurons
were RP11-442A13.1 and RP11-320L13.2, which map to 9q33.1
and Xq13.1, respectively (Table S6). The pseudogenes that
showed the most significant fold changes upon differentiation
were TDGF3 (teratocarcinoma-derived growth factor 3, pseudo-
gene; CRIPTO-3), which maps to Xq21.1, and RP11-492I2.1,
which maps to an ELAVL4 intron. ELAVL4 transcripts increase
significantly in our differentiating neurons and is induced in the
brains of PCP treated rats [46,76,89,90]. TDGF3 is expressed in
malignant cells and decreases upon differentiation of human
teratocellular carcinoma cells. Among the more interesting
pseudogenes that decrease in neurons are POU5F1P4, which is
derived from POU5F1, and TERF1P3 and TERF1P4. The parent
gene (TERF1) codes for a component of the telomere nucleopro-
tein complex.
Splice Variants
Neuron specific splicing is regulated by several proteins,
including NOVA1, a neuron specific RNA-binding protein, and
the splicing inhibitor PTBP1 (polypyrimidine tract binding
protein). PTBP1 expression decreases ,3-fold in day 10 neurons,
while NOVA1 expression increases ,3-fold, consistent with their
known effects on splicing in neuronal tissue. Our paired-end
sequence reads allowed us to identify 143,586 splice junctions in
iPSCs and 144,885 in day 10 neurons. Two examples are depicted
in Fig. 3, which shows the changes in splice isoforms that occur in
the SZ and ASD candidate gene, NRXN1. Expression across exons
19, 20 and 21 (asterisk in figure) is particularly interesting
considering the importance of splice variants in this region,
known as splice site 4, in determining glutamatergic vs GABAergic
differentiation [91,92]. We validated the apparent increase in
expression across splice site 4 in this region by qPCR, which
showed a 2.65-fold+/20.79 increase in neurons (p,0.05).
We also show splice isoforms in the SZ candidate gene NRG1.
Overall, NRG1 transcripts increase ,10-fold in day 10 neu-
rons and a rich array of splice isoforms that change during
differentiation is observed. We validated the splice variant formed
between exons 10 and 11 in the NRG1 protein isoform HRG-b2b
using qPCR (denoted by asterisk). As seen in the figure, a 12.7+/
20.79 fold increase was detected in differentiating neurons
(p,0.05).
These findings show that RNA-Seq using amplified RNA will
faithfully identify splice isoforms, and that dramatic changes in the
overall pattern of alternatively spliced transcripts in candidate
genes for neuropsychiatric disorders is an early event in neu-
rogenesis.
Relevance to neuropsychiatric disorders
As recently reported by Brennand et al., using neurons derived
from patient-specific iPSCs is a valuable resource for gene
expression profiling, which is the goal of our ongoing research
as well [1]. However, important information related to SZ, ASD
and BD pathogenesis can also be gleaned by studying molecular
events occurring during human neurogenesis, even in the absence
of patient vs control comparisons. For example, some of the most
dramatic changes in gene expression in differentiating neurons in
this study occur in genes involved in neuropsychiatric disorders
that code for transcription factors and chromatin modifying
enzymes. Subtle alterations in the expression of such genes during
neurogenesis caused by genetic or environmental factors have the
potential to induce long-lasting changes in neuronal and brain
function. Among the SZ, BD, and ASD candidate transcription
factors and chromatin modifiers that change dramatically in day
10 neurons are POU3F2, MYT1L, RFX4, ZNF804A, SMARCA2,
Figure 2. Validation by RT-PCR and qPCR in unamplified RNAs. Panel A, top band in each of the 4 sets is a beta-actin control; bottom band,
specific transcripts. Lane 1, iPSCs; lane 2, day 14 neurons; lane 3, day 27 neurons; lanes 4 and 5, fetal brain (9 and 20 weeks, respectively); lanes 6 and
7, adult prefrontal cortex; lane 8, no RT (negative control). Panel B, same as A, but no 9 week fetal sample (lane 4 is 20 week fetal brain and lanes 5
and 6 are adult prefrontal cortex. Panel C, qPCR for MIAT and CRNDE in iPSCs (white bar) and day 14 neurons (black bar). Relative changes in gene
expression were calculated using the 2
2DDCt method with b2-microglobulin (b2M) as a reference gene. Mean increase in transcripts in neurons was
statistically significant (p,0.05). Error bar is SD based on 3 or 4 replicates, each done in triplicate.
doi:10.1371/journal.pone.0023356.g002
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the polycomb repressive complex.
In addition, expression of a number of genes coding for
proteins involved in cell-cell adhesion, synaptogenesis and
trans-synaptic bridging that have been implicated in neuropsy-
chiatric disorders increase in these early differentiating
neurons. These include NRXN1, NRXN3, NLGN1, CTNNA2,
NCAM1 (and its modulator ST8SIA2), CHL1, ELAVL4 and
PCDH9 [93–116].
Another way RNA-Seq data can be useful in understanding the
underlying molecular and genetic basis of neuropsychiatric
disorders is to identify non-coding elements transcribed in
differentiating neurons that map to regions of the genome
implicated by GWAS or CNVs. Many SNPs associated with
neuropsychiatric disorders map to large introns or intergenic
regions that are far removed from coding elements or known
regulatory domains. This makes it difficult to appreciate the
biological relevance of the association signal; presumably associ-
ated SNPs are in LD with disease-causing, biologically active
variants.
One such SNP is rs893703, which maps to chromosome 3
(position139,250,649) within an RBP1 (retinol binding protein)
intron [117]. The SNP falls within a lncRNA that significantly
increases in expression in differentiating neurons, RP11-319G6.1
(Table S7). RP11-319G6.1 is transcribed in the opposite orienta-
tion from RBP1, the latter of which decreases in differentiating
neurons. RP11-319G6.1 expression was validated in a different
sample of differentiating neurons and is also expressed in fetal and
adult brain (not shown). Whether or not RP11-319G6 affects RBP1
expression or other genes, and is a factor in the positive association
found between rs893703 and SZ remains to be determined.
Retinoids, it should be pointed out, play a role in brain
development and have been implicated in SZ, although the
evidence is not strong [118,119].
Similarly the lncRNA RP11-586K2.1, which maps to chromo-
some 8 (89,044,236–89,749,363) contains a SNP (rs12527359)
found to be associated with SZ and BD in a GWAS meta-analysis
[120]. RP11-586K2.1 increases ,3.5-fold in differentiating
neurons. It should be viewed as a potential candidate gene for
this GWAS signal since the nearest coding genes to rs12527359
Figure 3. Splice variants in NRXN1 (panel A) and NRG1 (panel B). Asterisk in A shows splicing across exons 19, 20 and 21 (exons 20 and 21 are
only ,2 kb apart and appear superimposed in figure). Asterisk in B covers exons 10 and 11 in the NRG1 isoform HRG-b2b. Panel C shows qPCR and
relative changes in gene expression calculated using the 2
2DDCt method with b2-microglobulin (b2M) as a reference gene. Mean increase in
transcripts in neurons was statistically significant (p,0.05). Error bar is SD based on 3 or 4 replicates, each done in triplicate.
doi:10.1371/journal.pone.0023356.g003
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(receptor-interacting serine-threonine kinase 2), which are
,400 kb–1,000 kb away, respectively.
A list of coding and non-coding genes that are differentially
expressed in the RNA-Seq analysis that contain SNPs mapped in
several SZ, BD and ASD GWAS studies are shown in Table S7
[120–123].
Finally, our transcriptome analysis could be useful in narrowing
down candidate genes in well-defined large copy variants that have
been found in SZ and ASD; coding genes, lncRNAs and lincRNAs
that significantly change in differentiating neurons should be
viewed as feasible candidates underlying the psychiatric manifes-
tations of the copy variant. The CNVs we evaluated in this
manner were 22q11.2 del, 15q11.2 del, 15q13.3 del, 16p11.2 dup,
17q12 del, 1q21.1 del, and 3q29 del [98,124–132].
A total of 51 coding and non-coding genes in these CNVs are
differentially expressed during early neurogenesis (Table S7). Of
these a few appear to be particularly interesting, including the
nicotinic cholinergic receptor subunit gene CHRNA7, and QPRT,
which codes for quinolinate phosphoribosyltransferase, an enzyme
involved in metabolizing an endogenous exitotoxin (quinolinate)
implicated in Alzheimer Disease and Huntington Disease.
Interesting two genes coding for proteins involved in phosphati-
dylinositol glycan (GPI) anchor biosynthesis – PIGW (chr17) and
PIGX (chr3) – map to CNVs that are differentially expressed
during neurogenesis. GPI anchors are used in cells to attach
hydrophilic proteins to cell membranes. The hydrophobicity
WNT3A, a signal transduction pathway believed to be involved in
subsets of patients with SZ and BD, is increased by GPI-like
anchors [133].
Discussion
In this study we show that RNA from a limited sample can be
reliably amplified preserving quantitative changes and splice
isoform integrity. Several novel findings emerged, including the
discovery that lncRNAs that map to the HOXA and HOXB gene
loci are expressed early in neurogenesis, and that at least one,
HOXAIRM1, is expressed in fetal brain. Considering the effect of
HOTAIRM1 on HOXA gene expression and myelopoiesis, our
findings suggest a similar role in neurogenesis as well, but that
remains to be determined experimentally. Similarly, the two other
lncRNAs that map to HOX gene loci, RP11-357H14.12 and
AC036222.1, that increase in differentiating neurons are excellent
candidates for regulating HOX gene expression in the developing
brain. The HOX genes play a role in brain development by
determining rhombomere segmental identity, regional neural
identity and anterior posterior patterning during early embryo-
genesis [60,62]. Most of the work on the role of HOX genes on
brain development has been carried out in drosophila and mouse.
Using neurons derived from iPSCs will provide an opportunity to
study the regulation of these genes, their targets, and their
apparent lncRNA regulators in human tissue, in vitro.
Although analyzing the transcriptome during neurogenesis in
humans is inherently valuable on its own, we are primarily
interested in its application to neuropsychiatric disorders. These
goals are not mutually exclusive since some of these disorders -
notably SZ and ASD - have developmental origins and a primary
defect in neurogenesis has been suggested. The RNA-Seq findings
highlight the possibility of studying transcriptional/chromatin
regulators involved in these disorders, and their downstream
targets. Furthermore, unbiased genome wide transcriptome
analysis has directed our attention to GWAS SNP signals that
map to lncRNAs that increase in expression in differentiating
neurons. Mutations causing aberrant expression of these non-
coding RNAs represent very feasible candidates for the biologically
significant variants that presumably lie in LD with disease-
associated SNPs. Functional assays, such as studying the effects of
knocking down expression of these lncRNAs in differentiating
neurons, and targeted DNA resequencing in patients with SZ are
warranted.
Establishing a role for non-coding RNAs in a subset of patients
with neuropsychiatric disorders would add a new dimension to the
genetic heterogeneity already known to underlie SZ, ASD and BD
and would be consistent with the growing literature showing that
this class of genes play a role in brain development and neuronal
function. Two non-coding RNAs have previously been suggested to
be involved in SZ in subgroups of patients; DISC2 and AK127244
[84,134,135]. DISC2 is transcribed anti-sense to DISC1 exon 9 and
maps a few kilobases 39 the breakpoint of the 1:11 translocation that
first targeted DISC1 as a candidate gene in SZ. Antisense expression
across exon 9 could conceivably modulate alternative splicing
involving this exon. However, this has not been established
experimentally. AK127244 is immediately upstream of NRXN1,
and we previously showed that the two genes share a common
promoter [84]. While copy variation affecting NRXN1 is a fairly
regular occurrence in patients with ASD and SZ, there have also
beenafewexamplesofcopylossinASDinwhichonlyAK127244is
affected [136]. Although AK127244 and DISC2 transcripts were
detected in the differentiating neurons we cultivated there was no
significant change from that found in iPSCs.
Finally, RNA-Seq analysis revealed interesting aspects of
alternative splicing that occur in differentiating neurons. Although
this will be expanded in a subsequent paper, a few points are worth
mentioning. For example, as shown in this paper, the generation of
alternatively spliced isoforms in two candidate genes for SZ –
NRG1 and NRXN1 – is a very early event in neurogenesis. This is
consistent with the idea that abnormalities in neuronal migration
and/or synaptogenesis, potential underlying factors in SZ, may
begin as a gene expression programming problem in early
differentiating neurons (either during fetal development and/or
in the post-development brain).
In addition, novel splice isoforms were observed for the lncRNA
MALAT1. MALAT1 codes for an 8.7 kb transcript, which
generates a 7.5 kb RNA that localizes to nuclear speckles, and a
61 nucleotide tRNA-like cytoplasmic molecule of unknown
function produced by 39 processing [137]. Splice isoforms have
not been observed in studies showing Northern blots for MALAT1.
However, spliced ESTs in the MALAT1 gene locus that overlap
with apparent spliced exons in our study have been isolated
(UCSC Genome Browser, human EST track; Fig. S1). The
different isoforms found in iPSCs and neurons suggest that
MALAT1 produces alternative transcripts in a cell type specific
manner that could potentially modulate its role in pre-mRNA
processing. Such an effect would be consistent with the role of
nuclear speckles, cell type specific nuclear organization, and
nuclear architecture on the differentiation of neurons and other
cell types [74,138–140].
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in early differentiating neurons (Day_10_FPKM, fold
change in expression (ln fold-change), Uncorrected
p-values, and Type of primary gene.
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Table S3 Top coding genes: absolute expression in
iPSCs, day 10 neurons, and fold increase and decrease.
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Table S4 Top lincRNAs.
(XLS)
Table S5 Top lncRNAs.
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Table S6 Top pseudogenes.
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Table S7 Differentially expressed genes that map to
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Figure S1 Splice isoforms found in MALAT1 tran-
scripts. Top panel, iPSCs; bottom panel, day 10 neurons.
Continuous reads from adjacent exons depicted by thin line. Exon
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